Skip to content

Study · Non-randomized trial · n = 45 · 1984

11 results

Long-term calcitonin therapy in postmenopausal osteoporosis.

Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB, Sisom K, Chesnut CH 3rd

Metabolism: clinical and experimental1 Apr 1984Cited by 192 (Europe PMC)

PMID6423929 (opens in a new tab)DOI10.1016/0026-0495(84)90187-2 (opens in a new tab)PepBankPUB-06423929
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporosis, mean total body calcium did not differ significantly between salmon calcitonin and control throughout the study.

    In plain wordsIn postmenopausal osteoporosis, average total body calcium did not differ significantly between salmon calcitonin and control throughout the study.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeMean total body calcium
    Study

    n = 45

    Comparator
    Control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 units/d · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Although mean total body calcium (TBCa) was not significantly different between treated and control patients throughout the study, mean differences in the change in TBCa from baseline (treated minus control) were significant at 12, 18, and 26 months.
    3 context sentences
    Summary · context
    Results are presented from a 2-year controlled study evaluating the efficacy of 100 units synthetic salmon calcitonin/d in the treatment of postmenopausal osteoporosis.
    Summary · context
    All patients received 400 units D2 po qd and 1200 mg CaCO3 po qd.
    Summary · context
    The 21 control and 24 treated patients (mean age 65) were not statistically different at baseline.
  2. 02HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporosis, the total body calcium change favored salmon calcitonin over control significantly at 12 months.

    In plain wordsIn postmenopausal osteoporosis, total body calcium change significantly favored salmon calcitonin over control at 12 months.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseTotal body calcium change at 12 months
    Study

    n = 45

    Comparator
    Control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 units/d · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Although mean total body calcium (TBCa) was not significantly different between treated and control patients throughout the study, mean differences in the change in TBCa from baseline (treated minus control) were significant at 12, 18, and 26 months.
    4 context sentences
    Summary · context
    The mean slope of TBCa for treated patients, but not for controls, was significantly positive through 18 months.
    Summary · context
    Results are presented from a 2-year controlled study evaluating the efficacy of 100 units synthetic salmon calcitonin/d in the treatment of postmenopausal osteoporosis.
    Summary · context
    All patients received 400 units D2 po qd and 1200 mg CaCO3 po qd.
    Summary · context
    The 21 control and 24 treated patients (mean age 65) were not statistically different at baseline.
  3. 03HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporosis, the total body calcium change favored salmon calcitonin over control significantly at 18 months.

    In plain wordsIn postmenopausal osteoporosis, total body calcium change significantly favored salmon calcitonin over control at 18 months.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseTotal body calcium change at 18 months
    Study

    n = 45

    Comparator
    Control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 units/d · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Although mean total body calcium (TBCa) was not significantly different between treated and control patients throughout the study, mean differences in the change in TBCa from baseline (treated minus control) were significant at 12, 18, and 26 months.
    4 context sentences
    Summary · context
    The mean slope of TBCa for treated patients, but not for controls, was significantly positive through 18 months.
    Summary · context
    Results are presented from a 2-year controlled study evaluating the efficacy of 100 units synthetic salmon calcitonin/d in the treatment of postmenopausal osteoporosis.
    Summary · context
    All patients received 400 units D2 po qd and 1200 mg CaCO3 po qd.
    Summary · context
    The 21 control and 24 treated patients (mean age 65) were not statistically different at baseline.
  4. 04HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporosis, the total body calcium change favored salmon calcitonin over control significantly at 26 months.

    In plain wordsIn postmenopausal osteoporosis, total body calcium change significantly favored salmon calcitonin over control at 26 months.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseTotal body calcium change at 26 months
    Study

    n = 45

    Comparator
    Control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 units/d · 26 monthsAs given in this study (human).

    Source sentences

    Summary
    Although mean total body calcium (TBCa) was not significantly different between treated and control patients throughout the study, mean differences in the change in TBCa from baseline (treated minus control) were significant at 12, 18, and 26 months.
    4 context sentences
    Summary · context
    The mean slope of TBCa for treated patients, but not for controls, was significantly positive through 18 months.
    Summary · context
    Results are presented from a 2-year controlled study evaluating the efficacy of 100 units synthetic salmon calcitonin/d in the treatment of postmenopausal osteoporosis.
    Summary · context
    All patients received 400 units D2 po qd and 1200 mg CaCO3 po qd.
    Summary · context
    The 21 control and 24 treated patients (mean age 65) were not statistically different at baseline.
  5. 05HumanNon-randomized trialActivity measurement

    In postmenopausal osteoporosis, serum calcium was significantly lower with salmon calcitonin than control at 4 months.

    In plain wordsIn postmenopausal osteoporosis, blood calcium was significantly lower with salmon calcitonin than control at 4 months.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseSerum calcium at 4 months
    Study

    n = 45

    Comparator
    Control
    Outcome group
    Calcium Metabolism · Endocrine and hormones
    Studied dose
    100 units/d · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    At 4 months, serum calcium values were significantly lower in treated patients than in controls (mean difference, treated minus controls), but were not statistically different from controls at study completion.
    3 context sentences
    Summary · context
    Results are presented from a 2-year controlled study evaluating the efficacy of 100 units synthetic salmon calcitonin/d in the treatment of postmenopausal osteoporosis.
    Summary · context
    All patients received 400 units D2 po qd and 1200 mg CaCO3 po qd.
    Summary · context
    The 21 control and 24 treated patients (mean age 65) were not statistically different at baseline.
  6. 06HumanNon-randomized trialActivity measurement

    In postmenopausal osteoporosis, serum calcium did not differ significantly between salmon calcitonin and control at study completion.

    In plain wordsIn postmenopausal osteoporosis, blood calcium did not differ significantly between salmon calcitonin and control at study completion.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeSerum calcium at completion
    Study

    n = 45

    Comparator
    Control
    Outcome group
    Calcium Metabolism · Endocrine and hormones
    Studied dose
    100 units/d · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    At 4 months, serum calcium values were significantly lower in treated patients than in controls (mean difference, treated minus controls), but were not statistically different from controls at study completion.
    3 context sentences
    Summary · context
    Results are presented from a 2-year controlled study evaluating the efficacy of 100 units synthetic salmon calcitonin/d in the treatment of postmenopausal osteoporosis.
    Summary · context
    All patients received 400 units D2 po qd and 1200 mg CaCO3 po qd.
    Summary · context
    The 21 control and 24 treated patients (mean age 65) were not statistically different at baseline.
  7. 07HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporosis, the mean total body calcium slope was significantly positive with salmon calcitonin through 18 months.

    In plain wordsIn postmenopausal osteoporosis, total body calcium rose significantly with salmon calcitonin through 18 months.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseTotal body calcium slope
    Study

    n = 24

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 units/d · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    The mean slope of TBCa for treated patients, but not for controls, was significantly positive through 18 months.
    3 context sentences
    Summary · context
    Results are presented from a 2-year controlled study evaluating the efficacy of 100 units synthetic salmon calcitonin/d in the treatment of postmenopausal osteoporosis.
    Summary · context
    All patients received 400 units D2 po qd and 1200 mg CaCO3 po qd.
    Summary · context
    The 21 control and 24 treated patients (mean age 65) were not statistically different at baseline.
  8. 08HumanNon-randomized trialActivity measurement

    In postmenopausal osteoporosis, urinary calcium significantly increased during the first 4 months of salmon calcitonin therapy.

    In plain wordsIn postmenopausal osteoporosis, urine calcium significantly increased during the first 4 months of salmon calcitonin therapy.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseUrinary calcium during first 4 months
    Study

    n = 24

    Outcome group
    Calcium Metabolism · Kidney and urinary
    Studied dose
    100 units/d · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    Urine calcium increased significantly for the first 4 months in treated subjects and then declined to baseline levels.
    3 context sentences
    Summary · context
    Results are presented from a 2-year controlled study evaluating the efficacy of 100 units synthetic salmon calcitonin/d in the treatment of postmenopausal osteoporosis.
    Summary · context
    All patients received 400 units D2 po qd and 1200 mg CaCO3 po qd.
    Summary · context
    The 21 control and 24 treated patients (mean age 65) were not statistically different at baseline.
  9. 09HumanNon-randomized trialActivity measurement

    In postmenopausal osteoporosis, urinary calcium declined to baseline after its initial increase during salmon calcitonin therapy.

    In plain wordsIn postmenopausal osteoporosis, urine calcium returned to baseline after its initial increase during salmon calcitonin therapy.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseUrinary calcium after initial increase
    Study

    n = 24

    Outcome group
    Calcium Metabolism · Kidney and urinary
    Studied dose
    100 units/d · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Urine calcium increased significantly for the first 4 months in treated subjects and then declined to baseline levels.
    3 context sentences
    Summary · context
    Results are presented from a 2-year controlled study evaluating the efficacy of 100 units synthetic salmon calcitonin/d in the treatment of postmenopausal osteoporosis.
    Summary · context
    All patients received 400 units D2 po qd and 1200 mg CaCO3 po qd.
    Summary · context
    The 21 control and 24 treated patients (mean age 65) were not statistically different at baseline.
  10. 10HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporosis, salmon calcitonin produced significantly greater iliac crest total bone area than control at 2 years.

    In plain wordsIn postmenopausal osteoporosis, iliac bone samples showed significantly greater bone area with salmon calcitonin than control at 2 years.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreasePercent total bone area
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 units/d · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Iliac crest bone biopsies showed (1) a significantly greater percent total bone area in treated compared to control patients at 2 years, and (2) a significantly decreased percent resorbing surface in treated patients when evaluated by paired difference from baseline.
    3 context sentences
    Summary · context
    Results are presented from a 2-year controlled study evaluating the efficacy of 100 units synthetic salmon calcitonin/d in the treatment of postmenopausal osteoporosis.
    Summary · context
    All patients received 400 units D2 po qd and 1200 mg CaCO3 po qd.
    Summary · context
    The 21 control and 24 treated patients (mean age 65) were not statistically different at baseline.
  11. 11HumanNon-randomized trialEfficacy outcome

    In postmenopausal osteoporosis, salmon calcitonin significantly decreased iliac crest resorbing surface from baseline.

    In plain wordsIn postmenopausal osteoporosis, salmon calcitonin significantly reduced the bone surface undergoing breakdown compared with baseline.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreasePercent resorbing surface
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 units/d · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Iliac crest bone biopsies showed (1) a significantly greater percent total bone area in treated compared to control patients at 2 years, and (2) a significantly decreased percent resorbing surface in treated patients when evaluated by paired difference from baseline.
    3 context sentences
    Summary · context
    Results are presented from a 2-year controlled study evaluating the efficacy of 100 units synthetic salmon calcitonin/d in the treatment of postmenopausal osteoporosis.
    Summary · context
    All patients received 400 units D2 po qd and 1200 mg CaCO3 po qd.
    Summary · context
    The 21 control and 24 treated patients (mean age 65) were not statistically different at baseline.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.